What is the correct dosage of pemetinib? Medication timing and dose adjustment schedule

Pemigatinib is a targeted drug mainly used to treat metastatic or locally advanced cholangiocarcinoma, especially for patients with FGFR2 gene rearrangements. Understanding how to use pemetinib correctly is critical to ensuring efficacy and safety. The following is a detailed description of its usage, dosage, dosage, and dosage adjustment regimen.

The recommended dose of pemetinib is usually taken orally once daily, based on a 28-day treatment cycle. The standard treatment plan is to take 13.5 mg per day at a fixed time every day during the treatment cycle. Medications should be taken after meals as food may affect the absorption of the medication. After the treatment cycle, the patient needs to rest for 14 days before proceeding to the next treatment cycle. Doctors may adjust dosage based on patient tolerance.

During treatment, if the patient experiences serious side effects or adverse reactions, the doctor may adjust the dose. Depending on the patient's specific response, the dose may be reduced to 2 mg, or treatment may be suspended for a period of time to observe recovery of side effects. If the side effects subside, the patient can resume normal dosage under the guidance of a doctor. If the side effects are still severe, the drug may need to be stopped completely, and the specific adjustment plan needs to be determined based on the individual needs of the patient.
If a patient experiences severe side effects or has poor tolerance to the drug during treatment, the doctor may temporarily stop taking the drug for recovery until the side effects disappear or are significantly reduced. Patients should receive regular check-ups after stopping the drug to assess the effect of the drug on their condition. If side effects are effectively controlled, drug treatment can be gradually resumed according to the doctor's judgment, but strict monitoring and adjustment protocols must be followed.
When using pemetinib for a long time, patients need to regularly monitor the effectiveness and safety of the drug, especially liver function, kidney function and electrolyte levels. Patients should go to the hospital for regular check-ups, especially within the first few months of treatment. Monitoring liver function and other related indicators is very important to ensure the safe use of the drug. If any abnormal symptoms occur, such as jaundice, rash or other discomfort, patients should communicate with their doctor in time.
Reference: https://go.drugbank.com/drugs/DB15102